| Date | Title | Description |
| 23.06.2021 | CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan | |
| 23.06.2021 | Japan Lifeline : Receives Regulatory Approval for HeartLight X3 | June 23, 2021
To whom it may concern,
Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO (Code: 7575 TSE 1st Section)
Contact person: Kenji Yamada, Senior Vice President, Corporate Administration Headquarter... |
| 02.06.2021 | CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China | |
| 25.02.2021 | CardioFocus Announces The Publication Of HeartLight X3 Pivotal Study Data | |
| 02.02.2021 | CardioFocus Announces Expanded Partnership With Japan Lifeline | |
| 11.01.2021 | CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal
USA - English
France - Français
Portugal - Português
España - español | |
| 15.12.2020 | CardioFocus Announces 10,000 Patients Treated Worldwide | |
| 28.05.2019 | CardioFocus Raises $55M in Financing | - |
| 28.05.2019 | CardioFocus Raises $55M In Financing | CardioFocus, Inc., a Markborough, MA-based medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), completed a $55m round of financing.
The company’s current syndicate of institutional investors part... |
| 28.05.2019 | CardioFocus lands $55M in funding for product launches | Author: Zachary Comeau |
| 28.05.2019 | CardioFocus Secures $55 Million In Financing | CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the completion of a $55 million round of financing.
The company's current syndicate of institutional inves... |
| 29.03.2017 | CardioFocus Completes $20M Equity Financing | CardioFocus, Inc., a Marlborough, Mass.-based medical device manufacturer focused on advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), completed a $20m equity financing round.
The current syndicate of inst... |
| 07.01.2015 | CardioFocus raises $32m, inks Japanese distribution deal | CardioFocus this week reported a funding round worth nearly $32 million and said it inked a distribution deal in Japan for its HeartLight laser ablation system for treating atrial fibrillation.
Marlborough, Mass.-based CardioFocus said in a... |
| 03.05.2013 | CardioFocus raises $11M in debt round | Wall Street Beat | CardioFocus added $11 million to its coffers in a round of debt financing from Oxford Finance and Silicon Valley Bank as it commercializes its HeartLight endoscopic ablation system overseas and winds up enrollment in a pivotal U.S. trial.
C... |
| 01.05.2013 | CardioFocus Closes $11M Debt Financing Round | CardioFocus, a Marlborough, MA, USA-based medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), closed an $11m debt financing round.
Backers included Oxford Finance and... |
| 21.03.2011 | CardioFocus Receives $5M in debt financing from Silicon Valley Bank | CardioFocus, a Marlborough, Massachusetts-based medical device company developing technology to treat cardiac disorders, has received a $5m in debt financing from Silicon Valley Bank.
CardioFocus intends to use the funds to initiate its piv... |
| 28.02.2011 | CardioFocus Completes $30.6M Financing | CardioFocus, Inc., a Marlborough MA-based developer of an Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation, completed a $30.6m financing.
Investors include new backers Fletcher Spaght Ventures, Manatuck Hill... |
| 25.02.2011 | Catheter maker CardioFocus nets nearly $14M in funding round | CardioFocus counts KBL Ventures, Oxford Biosciences Partners, SV Life Sciences Advisors and H.I.G. Ventures as investors. The company raised $6 million in a debt offering in 2009 and another $5 million in an April 2010 offering of equity, d... |
| 25.02.2011 | CardioFocus reels in $14 million | Funding roundup | CardioFocus Inc. drummed up in nearly $14 million in a hoped-for $15.6 million funding round.
The Marlborough, Mass.-based company is developing a visually guided balloon catheter that uses a rotating laser to ablate the tissue surrounding ... |
| 22.02.2011 | Top device VC: Fix FDA or watch business go to Costa Rica | A Boston, Mass.-based venture capitalist and former Boston Scientific Corp. (NYSE:BSX) executive is adding his voice to the chorus of medical device stakeholders calling for an overhaul to the way the FDA regulates medical devices.
In a col... |
| 22.02.2011 | FDA regulations will send medical device companies out of US, VC warns | LaViolette is no stranger to the device market or to the FDA’s Center for Devices & Radiological Health. He spent 15 years at the Natick, Mass.-based device giant, with stops as president of the cardiology and international groups. His ... |
| 04.10.2010 | Industry Ventures raising $300 million fund | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| - | Industry Ventures raising $300 million fund | Industry Ventures, which invests in other venture and angel funds but has also made direct investments in healthcare, is raising a sixth fund after drawing down more than half of its 2-year-old, $265 million fund, according to VentureWire.
... |
| - | Catheter maker CardioFocus nets nearly $14M in funding round | Marlborough, Mass.-based catheter maker CardioFocus Inc. nets $13.7 million out of a possible $15.7 million round.
CardioFocus Inc. pulled in nearly $14 million in a hoped-for $16 million funding round, according to a regulatory filing.
The... |
| - | CardioFocus | “CardioFocus provides electrophysiologists with innovative and effective tools that bring precision and control to the treatment of atrial fibrillation.” |
| - | FDA regulations will send medical device companies out of US, VC warns | A Boston, Mass.-based venture capitalist and former Boston Scientific Corp. (NYSE:BSX) executive is adding his voice to the chorus of medical device stakeholders calling for an overhaul to the way the FDA regulates medical devices.
In a col... |
